Four major medical organizations have released comprehensive nutritional guidance for clinicians prescribing glucagon-like peptide-1 receptor agonists (GLP-1s) for obesity management, addressing challenges in medication adherence, side effects, and long-term efficacy. The guidance recommends evidence-based nutritional priorities, including assessments, dietary interventions, and management strategies for gastrointestinal side effects, to support GLP-1 therapy. It also emphasizes health equity considerations and outcomes, such as disparities in access to GLP-1s and the integration of Food is Medicine programs. The cost-effectiveness implications and implementation recommendations for effective treatment are discussed.

Source: Obesity Journal